ARRIVENT BIOPHARMA, INC. Increase (Decrease) in Prepaid Expense and Other Assets
ARRIVENT BIOPHARMA, INC. (AVBP) reported Increase (Decrease) in Prepaid Expense and Other Assets of $1.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$1.55M, a 132.66% decline year-over-year.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $2.56M, a 60.97% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$275.00K.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $6.49M.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $12.56M.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$1.46M.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$9.67M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.01M 10-Q · filed 2026-08-12 | $733.00K derived: sum of 3 quarters · filed 2026-08-12 | $7.22M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.56M 10-Q · filed 2026-05-11 | $2.29M derived: sum of 2 quarters · filed 2026-05-11 | $8.78M derived: sum of 3 quarters · filed 2026-05-11 | $13.53M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$275.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $6.21M derived: sum of 2 quarters · filed 2026-03-05 | $10.97M derived: sum of 3 quarters · filed 2026-08-12 | $12.56M 10-K · filed 2026-03-05 |
| 2025-09-30 | $6.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $11.24M derived: sum of 2 quarters · filed 2026-08-12 | $12.84M 10-Q · filed 2025-11-10 | $11.41M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $4.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $6.35M 10-Q · filed 2026-08-12 | $4.92M derived: sum of 3 quarters · filed 2026-08-12 | $4.62M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.59M 10-Q · filed 2026-05-11 | $163.00K derived: sum of 2 quarters · filed 2026-05-11 | -$135.00K derived: sum of 3 quarters · filed 2026-05-11 | -$381.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.73M derived: sum of 2 quarters · filed 2026-03-05 | -$1.97M derived: sum of 3 quarters · filed 2026-03-05 | -$1.46M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$298.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$544.00K derived: sum of 2 quarters · filed 2025-11-10 | -$36.00K 10-Q · filed 2025-11-10 | -$4.08M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$246.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $262.00K 10-Q · filed 2025-08-11 | -$3.78M derived: sum of 3 quarters · filed 2025-08-11 | -$5.96M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $508.00K 10-Q · filed 2025-05-12 | -$3.53M derived: sum of 2 quarters · filed 2025-05-12 | -$5.72M derived: sum of 3 quarters · filed 2025-05-12 | -$11.62M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$6.22M derived: sum of 2 quarters · filed 2025-03-03 | -$12.13M derived: sum of 3 quarters · filed 2025-03-03 | -$9.67M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$2.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$8.08M derived: sum of 2 quarters · filed 2024-11-14 | -$5.63M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$5.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$3.45M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $2.45M 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |